US biopharma Mineralys Therapeutics (Nasdaq: MLYS) is paying Tanabe Pharma to remove future royalty payments on lorundrostat, its experimental aldosterone synthase inhibitor for hypertension.
The Pharma Letter is a specialized business information platform dedicated to delivering timely, accurate, and unbiased news on the global pharmaceutical, biotechnology, and generic drug industries. Its editorial focus spans a broad spectrum of topics including medicine and healthcare, alternative medicine, pharmaceuticals, medical specialties, health and wellness, as well as key business and economic developments within these sectors.
Its readership primarily consists of industry executives, decision-makers in allied organizations, investors, analysts, policymakers, and professionals who require up-to-the-minute insights to inform their commercial strategies. The content is crafted for those who need to stay ahead in a rapidly evolving sector where fresh information can have significant impact on business decisions.
The Pharma Letter covers its subjects through a variety of journalistic approaches such as press releases from companies or government bodies; data-driven reports; private sector announcements; investment analysis; and coverage of regulatory or policy changes. This ensures that readers receive both immediate news updates as well as deeper analytical perspectives relevant to the industry’s commercial landscape.
Content from The Pharma Letter is accessible across multiple platforms including online digital print editions for real-time updates and archival research needs; traditional print publications for in-depth features; and podcasts that offer expert commentary or interviews with key figures in the field.
